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Introduction
The transition from CFC to HFA metered dose
inhalers has improved asthma therapy
Inhaled corticosteroids have been recommended by
national and international guidelines1 as the main-
stay for anti-inflammatory treatment in patients
with bronchial asthma. Inhaled corticosteroids are
delivered by a variety of devices such as pressur-
ized metered dose inhalers (pMDIs), dry powder
inhalers (DPIs) and nebulizers. The choice of the
devices is dependent on a number of clinical factors
such as severity of the disease, ability of the
patient to proper usage of the device and
the preference of the patient and the doctor. The
latter is not always based on strong arguments.
Inhalation therapy for treatment of bronchial
asthma is performed since more than 200 years
using ‘‘asthma cigarettes’’. The first Jet-Nebulizers
were brought up in the 1930s, and in 1956, the first
CFC-containing pMDI was marketed (Riker Mediha-
lers). These devices were mainly used to deliver
inhaled beta-agonists and anticholinergics to the
patient, with the benefit of rapid onset of action as
compared to the traditional oral route.2 It took
nearly 20 years to develop an inhaled corticosteroid
with limited side effects due to a significant first
pass metabolism. Dry powder inhalers were devel-
oped later. The majority of asthmatic patients is
using pMDIs worldwide. The popularity of these
devices is based on their design as they are easy to
use, small and portable. pMDIs designed by differ-
ent companies look much more alike than DPIs.
The effect of a certain drug delivered by the
respiratory route is dependent on a variety of
different factors which amongst others are the
ability of the patient to inhale correctly and to
produce a sufficient inspiratory flow. Drug deposi-
tion and the local and systemic metabolism of the
compound are important factors determining the
effect and the side-effects. Recently, the technol-
ogy to design and produce devices for respiratory
delivery has improved markedly. However in con-
trast to the progress in inhaler technology, adher-
ence and compliance to the recommended therapy
with inhaled corticosteroids remain a serious
problem which has to be minimized in order to
ensure the clinical benefit of inhaled corticoster-
oids in patients with bronchial asthma.
Chlorofluorocarbons (CFCs) have been used in
many products such as refrigeration, plastics, non-
medical aerosol, etc. pMDIs traditionally have been
formulated using CFC propellants 11 and 12. The
emission of CFCs into the atmosphere is harmful to
the ozone layer. This resulted in an Environmental
Program under the auspices of the United Nations,
and over 40 nations agreed to the Montreal protocol
in 1987 for the reduction and later for the cessation
of the use of CFCs.3 The production of CFCs was
stopped in 1996 except for ‘‘essential uses’’.
Essential uses included the manufacturing of pMDIs
containing drugs for patients with airway diseases
(asthma and COPD) and on therapy with pMDIs. The
European Commission (Strategy for the Phase-Out
of CFCs in Metered Dose Inhalers)4 decided later
the criteria according to which CFC containing
inhalers should be withdrawn.
After years of research in this area, hydrofluor-
oalkane (HFA) 134a (norflurane) was selected as a
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potential substitute for CFC in pMDIs. Many
pharmaceutical companies started programmes to
develop norflurane-based pMDIs containing b-ago-
nists and corticosteroids. The principal objective of
these research programs was a smooth transition
from CFC to non CFC pMDIs.
However, CFCs and HFAs share a number of basic
technical characteristics but differ in such physical
properties as density, vapor pressure, molecular
polarity and evaporation kinetics. Therefore, the
initial idea that CFC formulations can be translated
into HFA ones without any major changes was one
of the most cost-intensive mistakes of the pharma-
ceutical development. These differences have
necessitated the development of new formulations,
valves and manufacturing processes for HFA-134a
inhalers. However this technical research was a
potential milestone in aerosol therapy, as new
questions were raised, and new formulations like
the extrafine aerosols were developed.
Different topics have to be addressed when new
inhalers or propellants are developed. The first and
most important is that the active drug has to be
formulated with the propellant. The traditional
CFC devices contain the active drug in suspension,
but the active is, as in the case of beclometasone
and budesonide, partially soluble in norflurane; in
some instances drugs were reformulated as suspen-
sion formulations, while in other cases solutions
have been obtained with the use of a co-solvent.
For the replacement of CFC-containing propellant
two different strategies are available: one is
heading for an ‘‘extrafine’’ aerosol, resulting in
increased efficacy, but potentially reduced ther-
apeutic ratio. The other way is to leave the dose
and particle size as they are in the CFC-devices,
and the patients can continue with the same dose
they are used to.
The Chiesi Group has developed technical solu-
tions to allow phaseout of CFCs and replacement
with HFAs. The development program was aimed at
producing tailored particle aerosols which allow an
easy transition to CFC-free products because the
dose remains the same, but also optimize the
intrapulmonary deposition of the inhaled drugs.5
This last point reiterates the importance of the
small airways in bronchial asthma. To investigate
small airways is a real challenge as conventional
lung functions test are insufficient to differentiate
between the functional contribution of small versus
large airway. The introduction of methods to
investigate airway inflammation by invasive
(bronchoscopy, bronchoalveolar lavage) and non-
invasive (induced sputum, exhaled air, breath
condensate) techniques allowed new insights in
the distribution of airway inflammation along the
airways.6 Lung slices taken from human lungs
allowed to investigate small airways and to study
the response to pharmacologic interventions.7
Recent advantages in high-resolution computed
tomography imaging have allowed to study the
structure function relationship in the small airways
and in vivo assessment of drug deposition.8 Thus
the transition of CFC-based pMDIs to HFA containing
devices resulted not only in progress of inhaler
technology but prompted intensive research in the
field of small and peripheral airways which has
been neglected over the last few decades.
In this supplement of Respiratory Medicine a new
formulation of the well-known inhaled corticoster-
oid budesonide in HFA134a is presented. This is the
first available HFA-budesonide on the market and it
has been developed by Chiesi Group using the
proprietary technology Modulites. Key advantages
of the Modulites technology are stable and uniform
dose delivery of HFA-based formulations and flex-
ibility in tailoring the particle size distribution of
the cloud generated on actuation of the pMDI. The
new HFA-budesonide is a solution formulation and
has been designed to be equivalent in terms of
efficacy, safety and dose delivered to currently
marketed CFC-containing inhalers, so as to allow a
‘‘seamless’’ transition to the CFC-free pMDI.
In the first article, Ganderton et al.9 carefully
describe problems and solutions of the formulation
and evaluate the new CFC–free budesonide pMDI.
This study demonstrates the translation of im-
provements in designing pMDIs into clinical benefits
like reduction in oropharyngeal deposition.
Comparative clinical studies have to be made to
reassure that new formulations of established
treatments have the same safety and tolerability,
as well as equivalent efficacy of available drugs.
Therefore, in this issue of Respiratory Medicine two
studies are shown that report on the asthma
control, efficacy and safety profile of the new
HFA-budesonide formulation.
The aim of these studies was to show equivalence
of the HFA-budesonide as compared to the CFC-
containing pMDIs to assure a dose per dose
transition.
In the first study, Grzelewska-Rzymowska et al.10
showed no differences in efficacy and safety
between HFA and CFC-containing budesonide pMDI.
The second study of Vastagh et al.11 was capable
to show similar efficacy to the clinical parameters
like PEFR, rescue salbutamol use and symptom score
in mild to moderate asthmatic patients using either
CFC-budesonide or HFA-budesonide b.i.d., or the
identical daily dose of HFA-budesonide as a single
morning dose. A more or less identical efficacy
profile and safety profile was found. This is of special
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interest for the ongoing debate about the use of
once daily inhaled corticosteroids that are currently
under clinical assessment. It would be of special
interest if the HFA-budesonide is comparable to the
new inhaled steroids like ciclesonide or mometa-
sone, that claim for a once-daily application.
All studies presented here and those related to
the replacement of CFC by HFA containing pMDIs
are part of a challenging history leading to
improvements in asthma therapy.
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